Supplementary material has been published as submitted. It has not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica

Table SI. Baseline screening recommendation and their periodicity.

| Risk factor                        | Baseline screening   | Periodicity  |
|------------------------------------|--|--|
| Tobacco use                        | All adults should be inquired about tobacco consumption <sup>21-24</sup>   | • At every healthcare visit <sup>23,24</sup>   |
| Obesity                            | BMI calculation and waist circumference measurement <sup>21-24</sup>   | • At least annually <sup>23</sup>  |
| HTN                                | Blood pressure measurement in all adults (18 years or older) <sup>25,26</sup>  | <ul> <li>If &lt;120/80, every 5 years <sup>25,26</sup></li> <li>If 120-130/80-85, every 3 years <sup>25,26</sup></li> <li>If &gt;130/85, at least annually <sup>25,26</sup></li> </ul> |
| Dyslipidemia                       | • Men > 40 years old and women > 50 years of age or post-menopausal <sup>27</sup>  | • Interval for subsequent screening not provided <sup>24,27</sup>  |
|                                    | <ul> <li>Adults who are 20 years of age<br/>or older and not on lipid-<br/>lowering therapy <sup>28</sup></li> </ul>   | <ul> <li>Adults 20 to 39 years of age, at least<br/>every 4-6 years; For adults 40 to 75<br/>years of age, assess traditional CVRFs<br/>routinely <sup>23</sup></li> </ul>             |
|                                    |  | <ul> <li>Annual screening in middle-aged<br/>adults without CVRFs (men aged 45-<br/>65 years, women aged 55-65 years)<sup>29</sup></li> </ul>  |
| DM                                 | Fasting plasma glucose, HbA1c <sup>22,30</sup> • Testing should begin at 45 years <sup>30</sup>  | If results are normal, testing should be repeated at least every 3 years <sup>30</sup>   |
| 10-year risk of<br>CVD calculation | <ul> <li>SCORE2 in apparent healthy men &gt; 40 years old and in women &gt; 50 years of age or post-menopausal; SCORE2-OP in apparent healthy people ≥ 70 years <sup>24</sup></li> <li>Pooled cohort equations for adults 40 to 75 years of age <sup>23</sup></li> </ul> | • Every 4 to 6 years <sup>23,24</sup>  |

The clinical practice guideline on which each recommendation is based is mentioned in superscript at the end of each statement. BMI: Body Mass Index; CVD: Cardiovascular disease; CVRF: Cardiovascular risk factors; DM: Diabetes mellitus; ESC: European Society of Cardiology; HTN: Hypertension; \*\* In the survey question, considering the questionnaire was distributed in a European country, the discrepancy in the age at screening beginning was resolved in favor of ESC guidelines.

Table SII. Baseline characteristics of the dermatologists surveyed and AEDV members

|                      | Dermatologists surveyed | AEDV members |  |  |
|----------------------|-------------------------|--------------|--|--|
| Female, %            | 63.1                    | 48.3         |  |  |
| Fellows, %           | 8.7                     | 12.0         |  |  |
| Private activity*, % | 58.3                    | 82.2         |  |  |

AEDV: Spanish Society of Dermatology and Venereology (Academia Española de Dermatología y Venereología). \*With or without public activity.

Table SIII. Baseline characteristics of the rheumatologists surveyed and SER members

|                      | Rheumatologists surveyed | Rheumatologists from the SER |  |  |
|----------------------|--------------------------|------------------------------|--|--|
| Female, %            | 67.0                     | 61.0                         |  |  |
| Fellows, %           | 3.2                      | 15.9                         |  |  |
| Private activity*, % | 22.3                     | 29.4                         |  |  |

SER: Spanish Society of Rheumatology (Sociedad Española de Reumatología). \*With or without public activity.

Table SIV. Statin prescription multivariable analysis

|   | Univariable |            |         | Multivariable |             |         |
|---|-------------|------------|---------|---------------|-------------|---------|
|   | OR          | 95% CI     | p-value | OR            | 95% CI      | p-value |
| Specialty                                 |             |            |         |               |             |         |
| Dermatologists vs Rheumatologists         | 0.24        | 0.12-0.50  | < 0.001 | 0.04          | 0.01-0.16   | < 0.001 |
| Sex                                       |             |            |         |               |             |         |
| Men vs women                              | 1.08        | 0.54-2.16  | 0.82    |               | _           | _       |
| Practice setting                          |             |            | 0.702   |               |             | _       |
| Private vs Public                         | 0.81        | 0.30-2.20  | 0.678   |               | _           | _       |
| Private + public vs only public           | 0.73        | 0.33-1.59  | 0.420   |               | _           | _       |
| Years since completing residency training |             |            | 0.012   |               |             | 0.003   |
| 1-10 years vs resident                    | 2.20        | 0.25-19.24 | 0.476   | 1.82          | 0.11-29.90  | 0.674   |
| 10-20 years vs resident                   | 3.88        | 0.45-33.34 | 0.216   | 1.98          | 0.12-31.89  | 0.629   |
| 20-30 years vs resident                   | 2.48        | 0.28-21.70 | 0.413   | 1.49          | 0.08-26.46  | 0.785   |
| >30 years vs resident                     | 9.78        | 1.13-84.37 | 0.038   | 13.45         | 0.80-226.62 | 0.071   |
| Patients with psoriasis treated per month |             |            | 0.369   |               |             | 0.433   |
| 5-20 vs <5                                | 1.10        | 0.21-5.57  | 0.920   | 0.44          | 0.04-4.88   | 0.500   |
| >20 vs <5                                 | 1.75        | 0.36-8.59  | 0.489   | 0.80          | 0.07-9.21   | 0.859   |
| Specialized psoriasis outpatient clinic   |             |            |         |               | _           | _       |
| No  | _           | _          |         |               | _           | _       |
| Yes                                       | 1.76        | 0.86-3.59  | 0.122   | 7.93          | 2.06-30.59  | 0.003   |
| Research projects related to psoriasis    |             |            |         |               |             |         |
| No  | _           |            |         |               | _           |         |
| Yes                                       | 1.62        | 0.84-3.12  | 0.151   | 1.28          | 0.50-3.31   | 0.609   |
| University teaching including psoriasis   |             |            |         |               |             |         |
| lectures                                  |             |            |         |               |             |         |
| No  | _           | _          |         |               | _           |         |
| Yes                                       | 3.13        | 1.51-6.48  | 0.002   | 2.85          | 1.05-7.75   | 0.041   |

CI: Confidence interval; OR: Odds Ratio.